证券代码：688338 证券简称：赛科希德 公告编号：2024-039 北京赛科希德科技股份有限公司 关于以集中竞价交易方式回购公司股份比例达到总股 本 1%暨股份回购进展公告 一、 购股份的基本情况 北京赛科希德科技股份有限公司（以下简称"公司"）于 2024 年 6 月 26 日 召开第三届董事会第十三次会议，审议通过了《关于以集中竞价交易方式回购公 司股份方案的议案》，同意公司使用超募资金及自有资金以集中竞价交易方式回 购公司股份，回购资金总额不低于人民币 5,000 万元（含），不高于人民币 1 亿 元（含），回购价格不高于人民币 34.5 元/股（含），回购期限自公司董事会审 议通过本次回购股份方案之日起 12 个月内。具体内容详见公司于 2024 年 6 月 28 日在上海证券交易所网站（www.sse.com.cn）上披露的《北京赛科希德科技股份 有限公司关于以集中竞价方式回购公司股份方案的公告》（公告编号：2024-024）。 二、 回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购期间，公司回购股份占公司总股本的 ...

根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 证券代码：688338 证券简称：赛科希德 公告编号：2024-038 北京赛科希德科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/6/28，由董事长吴仕明先生提议 | | | | --- | --- | --- | --- | | 回购方案实施期限 | 2024 6 26 日~2025 年 6 月 25 日 | 年 | 月 | | 预计回购金额 | 5,000 万元~10,000 万元 | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | □用于转换公司可转债 | | | | | □为维护公司价值及股东权益 | | | | 累计已回购股数 | 994,531 股 | | | | 累计已回购股数占总股本比例 | 0.9370% | | | | 累计已回购金额 | 21,263,930.76 元 | ...

2024 年 11 月 1 日 公司研究 24Q3 营收增长放缓，利润端短期承压 事件：公司发布 2024 年三季度报告，2024 前三季度实现营业收入 2.27 亿元， 同比增长 10.89%；归母净利润 0.84 亿元，同比下降 4.74%；扣非归母净利润 0.82 亿元，同比下降 4.62%。其中，2024Q3实现营收0.67亿元，同比增长7.49%； 归母净利润 0.21 亿元，同比下降 24.15%；扣非归母净利润 0.20 亿元，同比下 降 23.73%。 营收增长放缓，利润端短期承压：2024 年第三季度公司实现营业收入 0.67 亿元， 同比增长 7.49%，环比下降 18.89%；实现归母净利润 0.21 亿元，同比下降 24.15%，环比下降 35.17%；实现扣非归母净利润 0.20 亿元，同比下降 23.73%， 环比下降 38.20%。费用率增加以及毛利率下降影响利润增长。 研发投入持续增加，向产业链上下游拓展：2024 年前三季度研发投入 1545.12 万元，同比增长 11.08%；其中 Q3 研发投入 515.30 万元，同比增长 3.04%， 占营业收入比 7.63%。公司依 ...

Financial Performance - The company's operating revenue for Q3 2024 was ¥67,495,889.25, representing a year-on-year increase of 7.49%[2] - The net profit attributable to shareholders for Q3 2024 was ¥20,935,412.10, showing a decrease of 24.15% compared to the same period last year[2] - The basic earnings per share for Q3 2024 was ¥0.20, down 23.08% year-on-year[3] - Total operating revenue for the first three quarters of 2024 reached CNY 226,525,212.72, an increase of 10.85% compared to CNY 204,274,725.08 in the same period of 2023[15] - Net profit for the first three quarters of 2024 was CNY 83,622,479.30, a decrease of 4.5% from CNY 87,815,791.89 in the previous year[16] - Basic earnings per share for the first three quarters of 2024 were CNY 0.79, down from CNY 0.83 in the same period of 2023[17] - The total profit for the first three quarters of 2024 was ¥100,688,114.37, compared to ¥100,506,046.09 in the same period of 2023, indicating a marginal increase of 0.18%[23] Research and Development - Total R&D investment for Q3 2024 amounted to ¥5,152,590.89, an increase of 3.04% year-on-year, accounting for 7.63% of operating revenue[3] - Research and development expenses increased to CNY 15,451,190.21, up 11.09% from CNY 13,910,260.67 year-over-year[15] - The company obtained one design patent for an automatic coagulation analyzer during the reporting period, enhancing its intellectual property portfolio[10] Assets and Liabilities - The company's total assets at the end of Q3 2024 were ¥1,725,939,627.31, reflecting a 1.15% increase from the end of the previous year[3] - As of September 30, 2024, the total assets of Beijing Saike Xide Technology Co., Ltd. amounted to CNY 1,725,939,627.31, an increase from CNY 1,706,235,918.32 at the end of 2023, reflecting a growth of approximately 1.36%[13] - The total liabilities decreased to CNY 90,582,818.73 from CNY 106,006,702.15, a reduction of about 14.58%[13] - The company's equity attributable to shareholders rose to CNY 1,635,411,695.61 from CNY 1,600,247,880.79, indicating an increase of approximately 2.07%[14] - The total cash and cash equivalents at the end of Q3 2024 were ¥1,033,087,738.83, down from ¥1,253,412,906.49 at the end of 2023[19] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥68,283,597.36, up 11.66% year-on-year[2] - The net cash flow from operating activities for Q3 2024 was ¥68,283,597.36, an increase of 11.8% compared to ¥61,153,055.00 in Q3 2023[19] - Cash inflow from operating activities totaled CNY 258,005,114.28, compared to CNY 250,803,741.50 in the previous year, reflecting a growth of 2.48%[18] - The cash flow from operating activities generated a net amount of ¥69,730,328.23, an increase of 14.3% from ¥61,147,698.24 in the first three quarters of 2023[25] - The total cash outflow from investment activities was ¥455,227,687.40, significantly higher than ¥87,782,142.16 in the same period last year, resulting in a net cash flow from investment activities of -¥253,787,553.15[19] - The company reported a net cash outflow from financing activities of -93,516,011.67 RMB, indicating a decrease in cash from financing sources[26] Operational Efficiency - The company completed a change of registered address to a new location in Daxing District, Beijing, which may facilitate operational efficiency[10] - The company's cash flow management strategies will be crucial for future growth and operational stability[26] - The company is focusing on market expansion and new product development as part of its strategic initiatives moving forward[16] Other Financial Metrics - The weighted average return on equity for Q3 2024 was 1.27%, down 0.5 percentage points year-on-year[3] - The total current assets as of September 30, 2024, were CNY 1,369,301,003.67, slightly down from CNY 1,382,294,540.94, a decrease of about 0.94%[12] - The company's retained earnings increased to ¥490,409,727.27 from ¥431,037,049.14 at the end of 2023, reflecting a growth of 13.8%[22] - The cash outflow for employee compensation increased to ¥44,934,295.56 from ¥42,427,896.28, marking a rise of 5.9%[19] - The cash outflow for taxes paid decreased to ¥36,888,429.50 from ¥44,532,800.88, a reduction of 17.3%[19]

证券代码：688338 证券简称：赛科希德 公告编号：2024-037 北京赛科希德科技股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会计政策变更是北京赛科希德科技股份有限公司（以下简称"公司"） 根据中华人民共和国财政部（以下简称"财政部"）发布的《企业会计准则应用 指南汇编 2024》而进行的相应变更，无需提交公司董事会、监事会和股东大会 审议。 本次会计政策变更不会对公司的财务状况、经营成果和现金流量产生重大影 响，不存在损害公司及股东利益的情形。 本次会计政策变更前，公司执行财政部发布的《企业会计准则——基本准则》 和各项具体会计准则、企业会计准则应用指南、企业会计准则解释公告以及其他 相关规定。 本次会计政策变更后，公司将按照《企业会计准则应用指南汇编 2024》的 相关规定执行。其他未变更部分，仍按照财政部前期颁布的《企业会计准则—— 基本准则》和各项具体会计准则、企业会计准则应用指南、企业会计准则解释公 告以及其他相关规定执行。 二、 本次会计政策变 ...

证券代码：688338 证券简称：赛科希德 公告编号：2024-036 北京赛科希德科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案实施期限 | 2024 6 年 6 月 25 | 年 | 月 | 26 | 日 | | --- | --- | --- | --- | --- | --- | | 预计回购金额 | 5,000 万元~10,000 万元 | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | □用于转换公司可转债 | | | | | | | □为维护公司价值及股东权益 | | | | | | 累计已回购股数 | 979,582 股 | | | | | | 累计已回购股数占总股本比例 | 0.9229% | | | | | | 累计已回购金额 | 20,897,862.89 元 | | | | | | 实际回购价格区间 | 19.92 元/股~22.77 元/股 | | ...

证券代码：688338 证券简称：赛科希德 公告编号：2024-035 北京赛科希德科技股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/6/28，由董事长吴仕明先生提议 | | | | | | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 6 日~2025 年 月 25 | 月 | 26 | 6 | 日 | | 预计回购金额 | 5,000 万元~10,000 万元 | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | □用于转换公司可转债 | | | | | | | □为维护公司价值及股东权益 | | | | | | 累计已回购股数 | 457,382 股 | | | | | | 累计已回购股数占总股本比例 | 0.4309% | | | | | | 累计已回购金额 | 9,950,854. ...

2024 年 8 月 23 日 公司研究 营收稳健增长，凝血诊断产品持续推出 ——赛科希德（688338.SH）2024 年中报点评 要点 事件：公司发布 2024 年半年度报告，2024H1 实现营业收入 1.59 亿元，同比增 长 12.40%；归母净利润 0.63 亿元，同比增长 4.15%；扣非归母净利润 0.62 亿 元，同比增长 3.63%。 点评： 营收稳健增长，净利润增速受转固影响：2024 年上半年度公司实现营业收入 1.59 亿元，同比增长 12.40%；实现归母净利润 0.63 亿元，同比增长 4.15%；实现 扣非归母净利润 0.62 亿元，同比增长 3.63%。受大兴基地项目完工结转固定资 产带来的折旧、摊销费用增加等因素的影响，净利润增速低于营业收入增速。 研发投入持续增加，凝血诊断产品持续推出：2024 年上半年公司研发投入 1029.86 万元，同比增长 15.59%，占营业收入比 6.48%。截至 2024 年 6 月 30 日，公司拥有专利 42 项，其中 14 项为发明专利。2024 年公司自主研发的凝血 流水线产品 SMART-8800 投入市场，配合高速凝血分析仪能够 ...

证券代码：688338 证券简称：赛科希德 北京赛科希德科技股份有限公司 投资者关系活动记录表 编号：2024-008 | --- | --- | --- | |------------------|---------------|----------------| | | □特定对象调研 | □分析师会议 | | 投资者关系活动类 | □媒体采访 | □业绩说明会 | | 别 | □新闻发布会 | □路演活动 | | | □现场参观 | 其他：电话会议 | 参与单位名称及人 员姓名 详见附件清单 时间 2024 年 8 月 22 日 地点 电话会议 | --- | |------------------| | 上市公司接待人员 | | 姓名 | 一、介绍公司 2024 年上半年经营情况 元，同比增长 12.40%；实现归属于上市公司股东的净利 润 62,723,289.61 元，同比增长 4.15%；实现归属于上 市 公 司 股 东 的 扣 除 非 经 常 性 损 益 的 净 利 润 62,263,601.73 元，同比增长 3.63%。截至 2024 年 6 月 30 日，公司总资产 1,726,631, ...

Financial Performance - The company reported a total revenue of RMB 500 million for the first half of 2024, representing a 20% increase compared to the same period last year[1]. - The company's operating revenue for the first half of 2024 was CNY 159,029,323.47, representing a year-on-year increase of 12.40% compared to CNY 141,480,462.56 in the same period last year[15]. - The net profit attributable to shareholders of the listed company was CNY 62,723,289.61, showing a growth of 4.15% from CNY 60,222,027.83 in the previous year[15]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 62,263,601.73, an increase of 3.63% from CNY 60,082,964.52 in the same period last year[15]. - The net cash flow from operating activities was CNY 52,117,971.79, up 14.03% from CNY 45,705,681.63 in the previous year[15]. - The gross margin improved to 60%, up from 55% in the previous year, due to cost optimization measures[1]. - The company achieved a gross profit margin of approximately 63.5% in the first half of 2024, compared to 62.8% in the same period of 2023[136]. - The total profit for the first half of 2024 was ¥77,012,467.50, an increase from ¥68,887,635.27, reflecting a growth of 11.6%[137]. User Growth and Market Expansion - User data indicates a growth in active users, reaching 1.2 million, which is a 15% increase year-over-year[1]. - The company expects a revenue growth forecast of 25% for the second half of 2024, driven by new product launches and market expansion strategies[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[1]. - The company has established a nationwide marketing service network covering 29 provinces, enhancing its market penetration[56]. - The company’s user base exceeded 10,000 domestic users, indicating strong market presence and customer engagement[58]. Research and Development - Research and development expenses increased by 30% to RMB 100 million, focusing on new diagnostic technologies and product innovation[1]. - The total R&D investment amounted to ¥10,298,599.32, representing a year-on-year increase of 15.59% from ¥8,909,717.59[41]. - R&D investment accounted for 6.48% of operating revenue, an increase of 0.18 percentage points compared to the previous year[41]. - The company has developed 15 core technologies and holds 42 patents, including 14 invention patents, showcasing its strong R&D and innovation capabilities[25]. - The company is focused on developing new products and technologies in the high-tech and rapidly growing in vitro diagnostic industry[20]. Product Development and Innovation - The company has launched two new diagnostic products, which are anticipated to contribute an additional RMB 50 million in revenue by year-end[1]. - The company launched the SF-9200 fully automated coagulation analyzer in February 2023 and plans to introduce the SMART-8800 coagulation line product in 2024, enhancing efficiency for medical terminals[25]. - The company is actively developing high-performance medical devices, such as the SMART-8800 coagulation line and SF-9200 automatic coagulation analyzer, to enhance market competitiveness[56]. - The company continues to develop new products in the coagulation diagnostic reagent core process, with ongoing research on the lupus anticoagulant detection reagent kit[37]. Market Trends and Industry Outlook - The Chinese in vitro diagnostic market is projected to continue growing, driven by an aging population and advancements in medical technology[20]. - The thrombus and hemostasis in vitro diagnostic market in China experienced a compound annual growth rate (CAGR) of 24.8% from 2015 to 2019[20]. - The overall trend for demand growth in the thrombus and hemostasis market remains positive despite short-term fluctuations due to healthcare cost controls[20]. - The market for thrombus and hemostasis in vitro diagnostics is expected to grow as clinical awareness improves, with a significant gap in application compared to developed countries[22]. Risks and Challenges - The company has identified potential risks related to regulatory changes and market competition, which are detailed in the risk factors section of the report[1]. - The company faces risks related to a single product structure and concentrated application fields, which may not meet future market demands[61]. - Increased competition in the thrombus and hemostasis market poses a risk to the company's operations[61]. - The company may encounter pricing risks due to stricter government regulations on medical device pricing as part of healthcare reforms[62]. Financial Position and Equity - Total assets at the end of the reporting period were CNY 1,726,631,712.32, which is a 1.20% increase from CNY 1,706,235,918.32 at the end of the previous year[15]. - The company's total equity at the end of the first half of 2024 is RMB 1,639,644,833.48, compared to RMB 1,544,376,675.61 at the end of the previous year[156]. - The company reported a profit distribution of RMB -27,597,020.00 for the first half of 2024, indicating a reduction in retained earnings[153]. - The total capital reserve at the end of the first half of 2024 is RMB 469,696,806.51, reflecting changes in the company's financial structure[154]. Compliance and Governance - The company emphasizes compliance with regulatory oversight and the consequences of violating share lock-up commitments[88]. - The company guarantees strict compliance with the commitments disclosed in the prospectus for its initial public offering and will take responsibility for any losses incurred by investors due to non-fulfillment of these commitments[106]. - The company has committed to ensuring that any share transfers after the lock-up period will not be below the issue price, adjusted for any stock dividends or splits[86]. Environmental Responsibility - Environmental protection investments during the reporting period amounted to 2.42 million yuan[77]. - The company implemented various environmental measures to ensure wastewater, noise, and solid waste emissions meet standards[80]. - The company has taken measures to reduce carbon emissions, promoting sustainable development practices[81].